Skip Navigation LinksHome > November 12, 2008 - Volume 22 - Issue 17 > Five-year outcomes of initial patients treated in Botswana's...
doi: 10.1097/QAD.0b013e3283129db0
Clinical Science

Five-year outcomes of initial patients treated in Botswana's National Antiretroviral Treatment Program

Bussmann, Hermann; Wester, C William; Ndwapi, Ndwapi; Grundmann, Nicolas; Gaolathe, Tendani; Puvimanasinghe, John; Avalos, Ava; Mine, Madisa; Seipone, Khumo; Essex, Max; deGruttola, Victor; Marlink, Richard G

Collapse Box


Background: Antiretroviral treatment (ART) initiatives have now been established in many sub-Saharan African countries showing early benefits. To date, few results are available concerning long-term clinical outcomes in these treatment programs.

Methods: Response to ART is described in the first HIV-1C-infected adults enrolled in the Botswana Antiretroviral Treatment Program in 2002. Data analysis was conducted on available longitudinal data up to 1st April 2007.

Results: Six hundred thirty-three severely immunodeficient patients with a median CD4+ cell count of 67 cells/μl were initiated on non-nucleoside reverse transcriptase inhibitor-based combination ART and followed for a median of 41.9 months. The median CD4+ cell count increases were 169, 302, and 337 cells/μl at 1, 3, and 5 years, respectively. The percentages of patients with a viral load of less than 400 copies/ml at 1, 3, and 5 years were 91.3, 90.1, and 98.3%, respectively. Seventy-five percent of patients did not miss a single, or missed only one, monthly ART pickup per year with a mean pickup rate of 92.5%. The Kaplan–Meier survival estimates [95% confidence interval (CI)] at 1, 3, and 5 years were 82.7% (81.2 and 84.3%), 79.3% (77.6 and 81.0%), and 79.0% (77.3 and 80.7%), respectively. At 6 months, the risk of treatment modification for anemia was 6.94% (5.9 and 8.0%) for cutaneous hypersensitivity reactions, 1.3% (0.8 and 1.7%), and 1.1% (0.7 and 1.6%) for hepatotoxicity.

Conclusion: This initial group of adults on ART in Botswana had excellent sustained immunologic, virologic, and clinical outcomes for up to 5 years of follow-up with low mortality among those surviving into the second year of ART.

Copyright © 2008 Wolters Kluwer Health, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.